1) BeeTan K, RaghuAdya S, FarhatullahKris C. Lewandows Paul O, Hendrik L, Harpal S. 2008.Omentin-1, a novel adipokine, is decreased inoverweight insulinresistant women with polycystic ovary syndrome journal Diabetes.57:801-808.
2) Dimas I, Julia K, Thomas R. 2010. Adipose tissue, inflammation and cardiovascular disease. Rev Assoc Med Bras. 56:116-21.
3) Francisca L, Rodolfo G, Juan J, GomezR, Carlos D, and Oreste G. 2009. Adipokines as novel modulators of lipid metabolism. 0968-0004.
4)Bilski J, Teleglow A, Zahradnik-Bilska J, Dembinski A and Warzecha Z. 2009.Effects Of exercise on appetite and food intake regulation. Med Sport.13:82-94.
5) Yang M,Yang G, Dong J, Liu Y, Zong H, Liu H, Boden G, Li L. 2007.Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J. Investig. 58;7 883–886.
6) De Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ. 2007.Omentin plasma levels and gene expression are decreased in obesity. Diabetes56: 1655-1661.
7) Saremi A, Shavandi N, Parastesh M, Daneshmand H. 2010.Twelve-Week Aerobic Training Decreases Chemerin Level and Improves Cardiometabolic Risk Factors in Overweight and Obese Men. Asian Journal of Sports Medicine.1: 3 151-158.
8) Zhong X, Zhong HY, Tan H, Zhou Y, Liu F, Chen F, Shang DY. 2011. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacologica Sinica. 32: 873–878.
9) Liu R, Wanga X, Bu P.2011. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract.93: 21 – 25.
10) Harris K. A Holly R.G.1987.Physiological response to circuit weight traning in borderline hypertensive subject. Medicine Science Sports Exercise.19 :3 246-252.
11) PeterKokkinosF, Puneet N, John A, Colleran D.O. Andreas P, Aldo NotargiacomoM.D, Domenic B.S,Reda M.S, and Vasilios Papademetriou M.D. 2007.Effect Of Regular Exercise On Blood Pressure And Left Ventricular Hypertrophy In African-American Men With Severe Hypertension. New England Journal Medicine. 333: 1462-7.
12) Choudhury A, Lip GY. 2005. Exercise and hypertention. Journal Human Hypertention. 19:8 585-7.
13) Tan BK, Adya R, Farhatullah S, Lewandowsk KC, O’Hare P, Lehnert H, Randeva HS. 2008. Omentin-1, a novel adipokine, is decreased overweight insulinresistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes. 57: 801-808.
14) Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y. 2011.Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochemical and Biophysical Research Communications. 409: 339-343.
15) Zhong X, Zhong HY, Tan H, Zhou Y, Liu F, Chen F, Shang DY. 2011.Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacologica Sinica. 32: 873–878.
16) Liu R, Wanga X, Bu P. 2011.Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract. 93: 21 – 25.
17) Chobanian AV.2007. Clinical practice. Isolated systolic hypertension in the elderly. New England Journal Medicine. 357 :8 789–96.
18) Turner MJ1, Spina RJ, Kohrt WM, Ehsani AA. Effect of endurance exercise training on left ventricular size and remodeling in older adults with hypertension. Journal Gerontol And Biology Science Medicine Science, 2000;55:4 245-51.